OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
OKYO Pharma Limited, a biopharmaceutical company focusing on ocular therapies, has announced the purchase of 35,000 of its ordinary shares by Panetta Partners Limited, an entity with a beneficial interest to the Executive Chairman Gabriele Cerrone. This acquisition increases Cerrone’s total shareholding to 28.58% of the company’s issued share capital. OKYO is also advancing its clinical trials, including a recently completed Phase 2 trial for its drug candidate OK-101, aimed at treating inflammatory dry eye disease and neuropathic corneal pain.
For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.
